

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Keith Biggadike</td> <td>08/03/2004</td> </tr> <tr> <td>Paul Jones</td> <td>08/03/2004</td> </tr> <tr> <td>Jeremy John Payne</td> <td>08/03/2004</td> </tr> <tr> <td>Glaxo Group Limited</td> <td>12/19/2011</td> </tr> </tbody> </table>		Name	Execution Date	Keith Biggadike	08/03/2004	Paul Jones	08/03/2004	Jeremy John Payne	08/03/2004	Glaxo Group Limited	12/19/2011
Name	Execution Date										
Keith Biggadike	08/03/2004										
Paul Jones	08/03/2004										
Jeremy John Payne	08/03/2004										
Glaxo Group Limited	12/19/2011										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>GlaxoSmithKline Intellectual Property Management Limited</td> </tr> <tr> <td>Street Address:</td> <td>980 Great West Road</td> </tr> <tr> <td>City:</td> <td>Brentford, Middlesex</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>TW8 9GS</td> </tr> </table>		Name:	GlaxoSmithKline Intellectual Property Management Limited	Street Address:	980 Great West Road	City:	Brentford, Middlesex	State/Country:	UNITED KINGDOM	Postal Code:	TW8 9GS
Name:	GlaxoSmithKline Intellectual Property Management Limited										
Street Address:	980 Great West Road										
City:	Brentford, Middlesex										
State/Country:	UNITED KINGDOM										
Postal Code:	TW8 9GS										
PROPERTY NUMBERS Total: 2											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Patent Number:</td> <td>6537983</td> </tr> <tr> <td>Patent Number:</td> <td>6878698</td> </tr> </tbody> </table>		Property Type	Number	Patent Number:	6537983	Patent Number:	6878698				
Property Type	Number										
Patent Number:	6537983										
Patent Number:	6878698										
CORRESPONDENCE DATA											
<p>Fax Number: (919)483-7977</p> <p>Phone: (919) 483-9552</p> <p>Email: rebecca.f.kerney@gsk.com</p> <p><i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i></p> <p>Correspondent Name: GlaxoSmithKline</p> <p>Address Line 1: Five Moore Drive, P.O. Box 13398</p> <p>Address Line 2: Global Patents - C.2111.2F</p> <p>Address Line 4: ResearchTrianglePark, NORTH CAROLINA 27709-3398</p>											
ATTORNEY DOCKET NUMBER:	PG4746-1 / PG4746D2 (JPR)										

NAME OF SUBMITTER:

James P. Riek

**Total Attachments: 8**

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page1.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page2.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page3.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page4.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page5.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page6.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page7.tif

source=PG4746-1US\_and\_PG4746D2US\_Assignment\_Transmittal#page8.tif

**RECORDATION FORM COVER SHEET  
PATENTS ONLY**

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies)**Keith BIGGADIKE (August 3, 2004)  
Paul JONES (August 3, 2004)  
Jeremy John PAYNE (August 3, 2004)  
Glaxo Group Limited (December 19, 2011)Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) \_\_\_\_\_ (see above)

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Joint Research Agreement  
☐ Government Interest Assignment  
☐ Executive Order 9424, Confirmatory License  
☐ Other \_\_\_\_\_

**2. Name and address of receiving party(ies)**Name: GlaxoSmithKline Intellectual Property Management Ltd.

Internal Address: \_\_\_\_\_

Street Address: 980 Great West RoadCity: Brentford, Middlesex

State: \_\_\_\_\_

Country: UK Zip: TW8 9GSAdditional name(s) & address(es) attached? ☐ Yes ☒ No**4. Application or patent number(s):**☐ This document is being filed together with a new application.

A. Patent Application No.(s)

B. Patent No.(s)

6,537,983

6,878,698

Additional numbers attached? ☐ Yes ☒ No**5. Name and address to whom correspondence concerning document should be mailed:**Name: GlaxoSmithKlineInternal Address: Global PatentsC.2111.2FStreet Address: Five Moore DriveP.O. Box 13398City: Research Triangle ParkState: NC Zip: 27709-3398Phone Number: (919) 483-9552Fax Number: (919) 483-7977Email Address: usciprtp@gsk.com**6. Total number of applications and patents involved: 1****7. Total fee (37 CFR 1.21(h) & 3.41) \$40.00**

- ☐ Authorized to be charged by credit card  
☒ Authorized to be charged to deposit account  
☐ Enclosed  
☐ None required (government interest not affecting title)

**8. Payment Information**a. Credit Card Last 4 Numbers -  
Expiration Date -b. Deposit Account Number 07-1392Authorized User Name James P. Riek**9. Signature:**

Signature

James P. Riek (Registration No. 39,009)

Name of Person Signing

Date

Total number of pages including cover sheet, attachments, and documents:

8

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

## ASSIGNMENT

WHEREAS I/WE, **Keith BIGGADIKE, Paul JONES and Jeremy John PAYNE** all of **Stevenage, Hertfordshire, GB** (hereinafter called "the inventor(s)") have invented or discovered **"FORMULATION FOR INHALATION COMPRISING A GLUCOCORTICOID AND A BETA 2-ADRENORECEPTOR AGONIST"** (hereinafter called "the invention") for which a patent application no. **10/066,961** was filed on **4 February 2002** in The United States of America and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/GB03/00485 filed **4 February 2003**)

**WHEREAS** the invention, being made in the course of my employment, belongs to my/our employer, namely **GLAXOSMITHKLINE SERVICES UNLIMITED** a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

**WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from **GLAXOSMITHKLINE SERVICES UNLIMITED** the whole right, title and interest in and to the invention and the application, and

**GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** have authorised and requested my/our making the application, and

**WHEREAS GLAXO GROUP LIMITED** a company organised and existing under and by virtue of the laws of England and Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from **GLAXOSMITHKLINE**

**RESEARCH AND DEVELOPMENT LIMITED** the whole right, title and interest in and to the invention and the application in respect of the United States of America;

**NOW, THEREFORE**, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE SERVICES UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXOSMITHKLINE SERVICES UNLIMITED**. **GLAXOSMITHKLINE SERVICES UNLIMITED** in turn hereby assigns and transfers to **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO GROUP LIMITED** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **GLAXO GROUP LIMITED**.

**AND GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers,

affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO GROUP LIMITED**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

**IN WITNESS** whereof and with effect from **4 February 2002** the inventor(s) and **Peter John GIDDINGS** as Attorney of both **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** by virtue of Powers of Attorney granted by **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** respectively have hereunto set their respective hands.

SIGNED by Keith BIGGADIKE:

K. Biggadike

Date: 3 AUGUST 2004

SIGNED by Paul JONES:

P. Jones

Date: 3<sup>rd</sup> August 2004

SIGNED by Jeremy John PAYNE:

Jeremy J. Payne

Date: 3. August 2004

SIGNED by **Peter John GIDDINGS** as the Attorney of each of **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**:

[Signature]

Date: 05 AUG 2004

This ASSIGNMENT is made on 19<sup>th</sup> December 2011 between:

- (i) Glaxo Group Limited, a company incorporated in England and Wales (registered number 00305979), whose registered office is at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN ("Assignor"); and
- (ii) GlaxoSmithKline Intellectual Property Management Limited, a company incorporated in England and Wales (registered number 7739397), whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS ("Assignee").

WHEREAS:

- (A) In a deed of assignment dated 1 October 2011 between the parties (the "Deed"), Assignor assigned to Assignee beneficial ownership of patents owned by Assignor that are referred to in the Fluticasone Furoate licence agreement dated 1 January 2007 (as amended) between Assignor and Glaxo Wellcome Manufacturing Pte Limited (the "Licence Agreement") as defined in the Deed. Assignor also undertook in the Deed to transfer such patents as directed by Assignee.
- (B) Assignee now wishes to transfer full legal title of these patents to Assignee.

THIS ASSIGNMENT PROVIDES as follows:

1. Interpretation

- 1.1 Patents means the patents and patent applications set forth on Schedule A, all reissues thereof and all Letters Patent granted on the patent applications set forth on Schedule A.

2. Assignment of Legal Title

- 2.1 Assignor hereby assigns for no consideration its entire right, title and interest in, to, and under, Patents, including the right to sue for past infringement to Assignee.

3. Registration of Assignment of Legal Title

- 3.1 Assignor hereby authorises and requests the Commissioner of Patents and Trademarks of the United States to issue the same to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this assignment.

4. Warranty

- 4.1 Assignor hereby warrants that it has the full right to convey the legal title to the Patents to Assignee, and that Assignor has not executed, and will not execute any agreement in conflict herewith.


5. Governing Law

- 5.1 This Assignment is to be governed by and construed in accordance with English law. Any matter, claim or dispute arising out of or in connection with this agreement whether


contractual or non-contractual, is to be governed by and determined in accordance with English law.

5.2 The parties irrevocably submit to and agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this agreement of its subject matter or formation (including non-contractual disputes or claims).

Signed on behalf of Glaxo Group Limited

  
\_\_\_\_\_  
NAME: Paul Williamson  
Authorised Signatory  
For and on behalf of  
Edinburgh Pharmaceutical Industries Limited  
POSITION: Corporate Director  
DATE: 19/12/2011

Signed on behalf of GlaxoSmithKline Intellectual Property Management Limited

  
\_\_\_\_\_  
NAME: Vaughn Walton  
Authorised Signatory  
For and on behalf of  
The Wellcome Foundation Limited  
POSITION: Corporate Director  
DATE: 19/12/2011



Schedule A

PG4153

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	03-Aug-01	09/958050	05-Sep-06	7101866
United States	Granted	06-Jul-06	11/428853	08-Dec-09	7629335
United States	Filed	19-Dec-08	12/339607		

PG4442

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	03-Aug-01	10/343842	03-Mar-09	7498321

PG4709

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	04-Feb-02	10/066964	15-Jun-04	6750210

PG4733

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	13-Aug-04	10/918779	02-Jun-09	7541350
United States	Filed	18-Aug-10	12/858940		
United States	Granted	04-Feb-02	10/067020	22-Feb-05	6858596

PG4734

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	13-Aug-04	10/918770	12-May-09	7531528
United States	Granted	04-Feb-02	10/066951	07-Sep-04	6787532

PG4735

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	04-Feb-03	10/503114	22-Sep-09	7592329

PG4736

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	22-Jul-02	10/200364	22-Feb-05	6858593

PG4739

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	04-Feb-02	10/066836	06-Jul-04	6759398

PG4740

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Filed	04-Feb-03	10/502966		

PG4746

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	28-Oct-02	10/281735	12-Apr-05	6878698
United States	Granted	04-Feb-02	10/066961	25-Mar-03	6537983

PG4874

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Granted	11-Sep-02	10/241658	17-Aug-04	6777400

PB61235

Country	Status	Application Date	Application Number	Grant Date	Patent Number
United States	Filed	06-Apr-06	11/910615		

PATENT